In breast tumor cells, the MAP17 expression level determines the sensitivity to bortezomib by inhibiting the cytoprotective effects resulting from bortezomib-induced NFκB nuclear translocation and autophagy [29]. This evidence concerns the gene NFKB1 and breast neoplasm.